Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06120348
Other study ID # NE_DED_003
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date August 31, 2023
Est. completion date August 31, 2024

Study information

Verified date November 2023
Source Nu Eyne Co., Ltd.
Contact Jinho Jung, Ph.D Candi.
Phone +821083113509
Email jinho.jung@nueyne.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to evaluate the efficacy and safety of applying pulse Electrical Stimulation around eye after laser keratoplasty (LASEK) in patients with dry eye syndrome.


Description:

Duration of study period (per participant): Screening period (0-4weeks). Intervention period (12weeks). Patient needs to visit site at least 8 times (Screening, baseline, 1 day, 3day, 1, 4, 8, 12weeks based on baseline). Baseline visit will be done on the day of surgery.


Recruitment information / eligibility

Status Recruiting
Enrollment 178
Est. completion date August 31, 2024
Est. primary completion date April 30, 2024
Accepts healthy volunteers No
Gender All
Age group 19 Years to 60 Years
Eligibility Inclusion Criteria: - Men and women aged 19 to 60 - Those who are scheduled to get LASEK surgery - Those who have had dry eye symptoms for more than 3 months. - According to the guidelines for diagnosing dry eye syndrome of Korean Corneal Disease Study Group, those who fall under Grade II or higher - Those who TBUT test results of less than 10 seconds - Those who OSDI score of 13 or higher - Those who agreed to use contraception using a medically acceptable method during the period of clinical trial among Women of child bearing potential (WOCBP). - A person who voluntarily agreed to participate in this clinical trial. Exclusion Criteria: - A person who has applied cyclosporin for the treatment of dry eye syndrome, drugs such as lipid-containing eye drops, topical steroid eye drops, IPL, etc., and medical devices for the treatment of dry eye syndrome within one month from the screening - A person with an uncontrollable systemic chronic disease. - Those who are allergic to drugs such as Fluorescein Solution or ophthalmic anesthetics - In a case where there is a history of receiving ophthalmic surgery known to affect the tear layer within the last 6 months (e.g., Cataract, Punctal plug insertion, Pterygium surgery) - A person who has eyelid diseases or structural abnormalities - A person with acute eye infection or inflammation of the eyeball not related to Meibomian gland dysfunction - A person with abnormalities in the eyelids or eyelashes - A person with an eye condition or ophthalmic disease that is considered unsuitable for surgery - A person who takes systemic drugs (e.g., tetracycline derivatives, antihistamine, isotretinoin) - Pregnant or lactating women - Those who can't understand or read the consent form of this clinical trial (e.g., illiterate or foreigners) - Any other cases that PI considers hard to participate in this clinical trial (e.g., heart-related problems, seizure, epilepsy. Patients transplanted metal or electronic device in head & neck. Patient suffering from unknown pain. Patients who are warned not to use our clinical trial device or is prohibited from using it (e.g., pacemaker user).) - Those who wore contact lenses within 72 hours before screening or who must wear contact lenses during the clinical trial period - Those who have taken the relevant systemic drugs (steroids, immunosuppressants, omega-3 and anticholinergic drugs, etc.) within 30 days from the date of screening - Those who are judged to have problems attaching electrodes due to inflammatory reactions or other dermatological problems in the skin around the orbit where the electrodes of medical devices are attached - Those who participated in other clinical trial within 30 days from the screening date

Study Design


Intervention

Device:
Charge-Balanced, Symmetric Nerve Stimulation
Charge-Balanced, Symmetric Nerve Stimulation device 30 mins once a day for 4weeks(28days) and twice a week from the 5weeks to the 12 weeks.
Sham Stimulation
Sham device 30 mins once a day for 4weeks(28days) and twice a week from the 5weeks to the 12 weeks.

Locations

Country Name City State
Korea, Republic of HanGil Medical Foundation Incheon
Korea, Republic of Department of Ophthalmology, Kangbuk Samsung Hospital Seoul
Korea, Republic of Department of Ophthalmology, Samsung Medical Center Seoul
Korea, Republic of Department of Ophthalmology, Severance Hospital Seoul
Korea, Republic of Kim's Eye Hospital Seoul
Korea, Republic of Nune Eye Hospital Seoul

Sponsors (1)

Lead Sponsor Collaborator
Nu Eyne Co., Ltd.

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in Tear break-up time (T-BUT) Check the changes in Tear break-up time (T-BUT) baseline, 12 weeks
Primary Changes in Visual Analogue Scale (VAS) score Check the changes in Visual Analogue Scale (VAS) score baseline, 1 week
Secondary Changes in Tear break-up time (T-BUT) Check the changes in Tear break-up time (T-BUT) baseline, 1, 4, 8 weeks
Secondary Changes in 5-Item Dry Eye Questionnaire (DEQ-5) and Ocular Surface Disease Index (OSDI) score Check the changes in 5-Item Dry Eye Questionnaire Dry Eye Questionnaire (DEQ-5) and Ocular Surface Disease (OSDI) score baseline, 1, 4, 8, 12 weeks
Secondary Changes in Visual Analogue Scale (VAS) score Check the changes in Visual Analogue Scale (VAS) score baseline, 3 days, 4, 8, 12 weeks
Secondary Changes in Staining Score Check the changes in Staining Score baseline, 1, 4, 8, 12 weeks
Secondary Changes in the length of the aesthesiometer's filament in centimeters Check the changes in the length of the aesthesiometer's filament in centimeters baseline, 1, 4, 8, 12 weeks
Secondary Changes in Tear Volume Check the changes in Tear Volume baseline, 1, 4, 8, 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT03216096 - Assessing Safety and Efficacy of DE-089 Ophthalmic Solution in Patients With Dry Eye Disease Phase 1
Completed NCT05825599 - PMCF Study to Evaluate Performance and Safety of "HPMC-based Eyedrops" Used to Relieve Dry Eye Symptoms N/A
Completed NCT04656197 - The Ocular Microbiome in Patients With Dry Eye Disease
Completed NCT05031806 - Evaluation of the Safety, Tolerability and Efficacy of iNexin™ for the Treatment of the Signs and Symptoms Associated With Dry Eye Disease Phase 1
Completed NCT03688802 - Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland Stimulation Phase 2
Completed NCT05213156 - Concentration of Ofloxacin Into the Aqueous Humour of Patients With Dry Eye Disease Phase 4
Completed NCT04548427 - Study to Evaluate the Efficacy and Safety of CKD-352 Phase 3
Completed NCT06176651 - Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers Phase 4
Completed NCT02254265 - Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca Phase 2/Phase 3
Completed NCT00395759 - The Visual Effect of an Investigational Artificial Tear in the Tear Layer. N/A
Completed NCT00680108 - A Study to Determine the Safety and Tolerability of Escalating Doses of INS365 Ophthalmic Solution Phase 2
Recruiting NCT06064071 - Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD N/A
Completed NCT04139122 - Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease Phase 1/Phase 2
Not yet recruiting NCT06375343 - Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive® Phase 1
Completed NCT01468168 - A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients Phase 2
Completed NCT01014078 - A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Dry Eye Disease Phase 4
Completed NCT00799682 - Exploratory Study Comparing Signs and Symptoms in Patients With Ocular Hypertension or Glaucoma Using Xalatan R® or Travatan Z® Phase 4
Completed NCT05082974 - Investigator Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease Following Laser-assisted in Situ Keratomileusis (LASIK) Phase 3
Recruiting NCT06146881 - Effectiveness of Diquafosol Prophylactic Therapy to Prevent Dry Eye Disease for Cataract Surgery Patients in Indonesia Phase 2
Completed NCT03292809 - CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) Phase 2/Phase 3